3 FTSE Shares Hitting New Highs: Drax Group Plc, Smith & Nephew plc and AstraZeneca plc

Drax Group Plc (LON: DRX), Smith & Nephew plc (LON: SN) and AstraZeneca plc (LON: AZN) are soaring.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

The prospects of the FTSE 100 (FTSEINDICES: ^FTSE) regaining May’s 13-year high of 6,876 points is looking increasingly bleak, with the index of top UK shares looking set for its fifth week of losses in a row. By late afternoon today it’s down 3 points on the day to 6,507, down 144 on the week, and 369 points short of that record — and that comes after the government lifted its economic forecasts and the Bank of England maintained its low-interest stance.

But there are still plenty of individual shares climbing ever higher. Here are three from the FTSE indices setting new records of their own:

Drax Group

Shares in Drax Group (LSE: DRX) have been climbing strongly since the power-station operator’s third-quarter update told us “we now anticipate that full year EBITDA and underlying earnings per share for 2013 will be materially ahead of current market consensus forecasts“.

Since the end of the first half, Drax’s performance from its coal-fired stations has been good, and its first biomass unit has been “encouraging“. Powers sales contracts are also going well, with contracts for 2014 up to 20.5 TWh, which is already close to this year’s 25.6 TWh.

As a result, the share price has spiked up to a 52-week high of 799p today, taking it up 40% over the past 12 months.

Smith & Nephew

Smith & Nephew (LSE: SN) set a new 52-week closing high yesterday of 831p, and so far today is ahead of that at 833p to take the shares up nearly 25% over the past 12 months.

The orthopedics specialist has recorded relatively modest year-on-year earnings rises, with a pretty flat year expected this year followed by a forecast 12% rise in 2014. That puts the shares on a P/E of 18 this year, higher than the FTSE’s average of 14, but that drops to under 16 on 2014 forecasts.


AstraZeneca (LSE: AZN) (NYSE: AZN.US) has been bouncing around its 52-week high in recent days, and after having touched the heights of 3,529.5p on Tuesday, the price could only manage 3,482.5 today — but that’s still more than 15%  up over the past 12 months and ahead of the FTSE. And that’s a strong endorsement of the firm’s refocus plans since chief executive Pascal Soriot took the helm — at Q3 time he said “We continue to focus on the strategic priorities of returning to growth and achieving scientific leadership, and this is reflected in continued investment in our growth platforms and our pipeline“.

We still have a couple of years of stagnating earnings forecast, but AstraZenenca’s P/E for year-end is a modest 11.3 and there’s an attractive 5% dividend yield expected.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

> Alan does not own any shares mentioned in this article. The Motley Fool owns shares in Smith & Nephew.

More on Investing Articles

Modern suburban family houses with car on driveway
Investing Articles

Should I snap up Taylor Wimpey shares at £1.30?

With the Taylor Wimpey share price down by almost 30% this year, should I snap up some shares while it's…

Read more »

Young female analyst working at her desk in the office
Investing Articles

How I’m finding shares to buy now – and keep for a decade

Our writer has been looking for shares to buy using an approach that looks both at long-term profit prospects and…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

What’s happening to the Petrofac (PFC) share price?

The Petrofac (LON:PFC) share price has had a seriously erratic year so far. I take a look at the latest…

Read more »

Young black woman in a wheelchair working online from home
Investing Articles

The Aviva share price is flying! Should I buy this 7% yield?

Despite recent gains, Roland Head thinks the Aviva share price could still be too cheap.

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

Here’s 1 passive income opportunity not to be missed!

This Fool details a passive income opportunity that could bolster his holdings, and the shares trading at cheap levels too.

Read more »

Young brown woman delighted with what she sees on her screen
Investing Articles

The Legal & General share price is dirt-cheap with a juicy dividend yield!

Jabran Khan takes a closer look at the Legal & General share price which looks like an opportunity to boost…

Read more »

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

If I’d invested £1,000 in this top lithium stock 5 years ago, here’s how much I’d have now!

This lithium stock has gone from strength to strength over the past year. But has it flown too high, or…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

A growth stock with a price-to-earnings ratio of just 9.7! Should I buy Yalla?

I'm generally not too keen on investing in dollar-demonated stocks at the moment. But Yalla, with its low price-to-earnings ratio,…

Read more »